---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-064796"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2026-06-03T20:57:09+00:00"
generated_at: "2026-06-03T21:07:59.461863+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals Plans to Seek FDA Priority Review Voucher for Tafenoquine in Babesiosis

## Summary
- Company intends to apply for a Commissioner's National Priority Review Voucher if trial results support NDA submission by Q1 2028.
- Tafenoquine is being evaluated in a randomized, placebo-controlled trial for patients hospitalized with severe babesiosis.
- Application depends on interim or final analysis of the severe babesiosis trial supporting a New Drug Application.
- Disclosure is provided to inform investors of current development and regulatory plans, subject to forward-looking risks.

## SEC filing metadata
- accession: 0001213900-26-064796
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2026-06-03T20:57:09+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390026064796/0001213900-26-064796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390026064796/ea0293532-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-064796
- JSON: https://secwatch.observer/filing/0001213900-26-064796.json
- Plain text: https://secwatch.observer/filing/0001213900-26-064796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.